Clinical Study
Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
Table 1
Baseline characteristics of retinopathy of prematurity infants receiving intravitreal conbercept or ranibizumab.
| | Intravitreal conbercept | Intravitreal ranibizumab | |
| No. of eyes (infants) | 29 (15) | 25 (13) | — | Mean GA (weeks) | 28.96 ± 2.36 (26.14–33.43) | 28.76 ± 2.25 (25.43–33.43) | 0.817 | Mean BW (g) | 1168.8 ± 344.5 (850–2100) | 1255.0 ± 356.9 (760–1950) | 0.522 | Male sex (%) | 60% | 61.54% | 0.934 | Mean PMA at first treatment | 41.22 ± 4.39 (36.29–50.14) | 39.42 ± 2.77 (36.00–44.86) | 0.075 | Mean injection times | 1.28 ± 0.45 (1–2) | 1.56 ± 0.65 (1–3) | 0.074 | Mean PMA at FA (weeks) | 88.66 ± 10.88 (71.29–115.43) | 98.02 ± 25.28 (65.57–133.71) | 0.251 |
|
|
GA, gestational age; BW, birth weight; PMA, postmenstrual age; FA: fluorescein angiography. Data are mean ± SD(range).
|